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Abstract
Background: Patients with Panic Disorder (PD) direct their attention towards potential threat, followed by panic attacks, and
increased sweat production. Ones own anxiety sweat odor influences the attentional focus, and discrimination of threat or
non-threat. Since olfactory projection areas overlap with neuronal areas of a panic-specific fear network, the present study
investigated the neuronal processing of odors in general and of stress-related sweat odors in particular in patients with PD.
Methods: A sample of 13 patients with PD with/ without agoraphobia and 13 age- and gender-matched healthy controls
underwent an fMRI investigation during olfactory stimulation with their stress-related sweat odors (TSST, ergometry) as well
as artificial odors (peach, artificial sweat) as non-fearful non-body odors.
Principal Findings: The two groups did not differ with respect to their olfactory identification ability. Independent of the
kind of odor, the patients with PD showed activations in fronto-cortical areas in contrast to the healthy controls who
showed activations in olfaction-related areas such as the amygdalae and the hippocampus. For artificial odors, the patients
with PD showed a decreased neuronal activation of the thalamus, the posterior cingulate cortex and the anterior cingulate
cortex. Under the presentation of sweat odor caused by ergometric exercise, the patients with PD showed an increased
activation in the superior temporal gyrus, the supramarginal gyrus, and the cingulate cortex which was positively correlated
with the severity of the psychopathology. For the sweat odor from the anxiety condition, the patients with PD showed an
increased activation in the gyrus frontalis inferior, which was positively correlated with the severity of the psychopathology.
Conclusions: The results suggest altered neuronal processing of olfactory stimuli in PD. Both artificial odors and stress-
related body odors activate specific parts of a fear-network which is associated with an increased severity of the
psychopathology.
Citation: Wintermann G-B, Donix M, Joraschky P, Gerber J, Petrowski K (2013) Altered Olfactory Processing of Stress-Related Body Odors and Artificial Odors in
Patients with Panic Disorder. PLoS ONE 8(9): e74655. doi:10.1371/journal.pone.0074655
Editor: Ben J. Harrison, The University of Melbourne, Australia
Received January 24, 2013; Accepted August 8, 2013; Published September 24, 2013
Copyright: ß 2013 Wintermann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for the present study was provided by the Medical Faculty of Dresden University of Technology. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gloria.wintermann@uniklinikum-dresden.de
Introduction
Panic disorder (PD) is characterized by sudden bursts of panic
attacks accompanied by heart palpitations, dizziness, trembling,
and sweating [1,2]. Until now, the exact pathophysiological
mechanism which triggers panic attacks has not been understood
completely [3]. The neuroanatomical model of PD suggests a
general disturbance of information processing with an attentional
bias for threat-related stimuli from the environment [4,5]. Besides
visuospatial stimuli, auditory stimuli or cognitive misinterpreta-
tion, recent findings suggest olfactory stimuli as relevant triggers or
at least catalysts for panic attacks [6,7]. During the state of anxiety,
an individuals own anxiety sweat conveys information about the
possible threat of a situation. The release of chemosensory anxiety
signals influences the attentional focus on vigilance and facilitates
the discrimination between threat and non-threat [8,9,10,11,12].
Thus, the perception of ones own anxiety sweat odor might
function as a chemosensory feedback system which might trigger
or catalyze panic attacks in patients with PD [10,13].
Since anxiety sweat is processed much faster than other
olfactory stimuli [14,15,16], specific brain areas relevant for the
representation of the social and emotional significance of stimuli
(amygdalae, cingulate cortex) and attentional regulation (thalamus,
parietal cortex) are involved [9,17,18,19,20,21,22]. Moreover, the
neuronal processing of anxiety sweat is localized in areas
associated with the regulation of empathetic feelings (insula,
precuneus, cingulate cortex), attentional control (dorsomedial
prefrontal cortex, dmPFC), and emotional control (cerebellum,
vermis) [20]. These areas which are mainly involved in the
regulation of emotions, memory, and attentional control have
been shown to be altered in patients with PD
[5,7,23,24,25,26,27,28,29]. Most fMRI studies showed the
involvement of the amygdalae as central fear structure with
increased activation [5,27,28,30] under the stimulation with
threat-related stimuli, emotional conflict detection (e.g. emotional
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Stroop task, [5]; face-word-pairs, [27]), and the occurrence of
panic [7] or decreased activation under the presentation of fearful
face-stimuli [25]. Also, studies could show the involvement of the
anterior/posterior cingulate cortex with either decreased activa-
tion under the stimulation with fearful stimuli [25] or increased
activation under the presentation of happy face stimuli [26],
neutral face stimuli [25], threat-related words [24], and under the
imagery of severe anxiety [23]. Increased activation of the
hippocampus, the orbitofrontal cortex, and the inferior frontal
cortex could be shown in patients with PD when compared with
healthy controls under the imagery of severe vs. neutral anxiety
conditions [23]. Furthermore, enhanced activation of the inferior
frontal gyrus has been demonstrated using the presentation of
agoraphobia-specific pictures [30] and differential conditioning
[31].
Alterations within three major neuronal networks have been
associated with the aetiopathogenesis of PD [4,29]. Recent
findings showed an increased resting state functional connectivity
of the amygdalae with the posterior cingulate cortex, the
precuneus, and the occipital cortex in the limbic network [29].
Aberrant connectivity of the dorsal anterior cingulate cortex with
the pre- and postcentral gyrus has been found in a so-called
salience network [29]. According to the neuroanatomical model of
PD, an abnormally sensitive fear-network is associated with the
occurrence of panic [4,32]. This model postulates an aberrant
stimulus processing from the cortex and the brainstem, which
leads to an excitatory input to the amygdalae that evaluates
sensory input in terms of potential threat. The amygdalae are
reciprocally connected with parts of the brainstem, the sensory
thalamus, the insula, the medial prefrontal cortex, and the
cingulate cortex. According to this model, the amygdalae can be
directly excited via input from the medial prefrontal and primary
somatosensory cortex, which has been associated with the
misinterpretation of somatic information [4,32]. Via efferent
projections to the medial hypothalamus and the nuclei of the
brainstem, the panic-type behavioural, endocrine, and autonomic
responses are released. Above all, afferent projections from the
hippocampus can directly stimulate the amygdalae [32]. Thus, the
neuronal areas which are functionally altered in patients with PD
(limbic or fear network and salience network) overlap with
neuronal areas of the olfactory system and the neuronal areas
involved in the processing of anxiety sweat odor [4,5,23,24,29,32].
However, studies in patients with PD considering the functional
neuronal representation of olfactory stimuli, especially fear-related
olfactory stimuli, are lacking. To which extent fear-related
olfactory stimuli can trigger a panic-specific fear network in PD
is unknown. Therefore, in the present study ones own anxiety
sweat odor was presented during fMRI and contrasted with a
stress-related sweat control odor (bicycle ergometry) and non-fear-
related artificial odors (peach odor, artificial sweat odor). Due to
the overlap of the panic-specific fear network with the projection
areas of the olfactory system (e.g. amygdalae, orbitofrontal cortex,
insula, hippocampus, thalamus) it can be assumed that the
neuronal processing of odors in patients with PD may be altered,
in general [4,33,34]. Furthermore, previous studies were able to
show that especially fear-related odors activate neuronal areas
where patients with PD show alterations which are likewise part of
the limbic network (e.g. amygdalae, cingulate cortex, insula,
precuneus, dmPFC/inferior frontal gyrus) [9,20]. Since patients
experiencing severe panic show an exaggerated activation of the
sympathico-adrenomedullary system accompanied by enhanced
sweating [35] it is assumed that a patients own anxiety sweat odor




The present investigation was performed according to the
Declaration of Helsinki on Biomedical Research Involving Human
Subjects and was approved by the University of Dresden Medical
Faculty Ethics Review Board (EK: 24022009). After description of
the complete study protocol participants signed in a written
informed consent.
Participants
Participants for the study were recruited in an outpatient unit of
the clinic for psychosomatic medicine and psychotherapy at the
University Hospital of the Dresden University of Technology,
Dresden, Germany from June 2009 to January 2011. The
Structured Clinical Interview (SCID) [36,37] for the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV) was used to
ascertain a diagnosis of panic disorder with agoraphobia [38]. The
patients did not suffer from any other mental disease in their
lifetime, and were free of any medication. Female participants
were permitted to use oral contraceptives (see Table 1). The
healthy individuals were recruited by public advertisements.
For the evaluation of the depressive symptomatology, the Beck-
Depression Inventory (BDI, [39]) was used. For the evaluation of
psychological impairment, the Symptom-Check-List (SCL, [40])
was applied. The Panic and Agoraphobia-Scale (PAS, [41]) was
used to assess the symptom severity for phobic anxiety. Moreover,
to assess body-related anxiety, cognitions, and avoidance, the Body
Sensations Questionnaire (BSQ, [42]), the Agoraphobic Cogni-
tions Questionnaire (ACQ, [42]) and the Mobility Inventory (MI,
[43]) were used. The extent of state and trait anxiety was assessed
with the State-Trait-Anxiety-Inventory (STAI, [44]).
Of the N=14 (seven females, seven males) patients participating
in the present study, one had to be excluded because the patient
broke off the fMRI examination. The remaining patient sample
consisted of six females and seven males (mean age = 31.10, SD
=13.01).
Of the group of healthy controls (N= 17, eight females, nine
males) four participants had to be excluded because of frontal
signal loss in one patient, a cyst at the neuro-pituitary in another
patient, and another two patients due to technical problems with
the olfactometer.
The healthy controls (six females, seven males, mean age
= 24.82, SD =4.52) were matched to the patients by age and
gender. There were no significant differences to the patients with
respect to age, gender, use of contraceptive pills, menstrual cycle,
smoking, body mass index (BMI), and alcohol consumption (see
Table 1). The patients with PD had significantly higher scores on
the PAS, the depression scale, and the general symptom index of
the SCL as well as higher trait anxiety than healthy controls. The
patients more often had anxious cognitions and more frequently
avoided agoraphobic situations, alone or accompanied, than the
healthy controls (Table 1).
All participants were right-handed and did not have any
neurological diseases (e.g. epilepsy), acute or chronic nasal or
respiratory diseases (e.g. rhinitis, sinusitis, hyposmia, anosmia), and
were without medication with an impact on the olfactory system
(e.g. ACE inhibitor, psychotropic drugs). Normal olfactory
function was ascertained with the odor identification task using
the ‘‘Sniffin’ Sticks’’ test kit [45,46]. The two groups did not differ
with respect to odor identification and all the participants showed
normal olfactory function [T= .000, df = 24, p = 1.000; patients vs.
controls, mean (SD): 10.54 (.88) vs. 10.54 (1.39)]. Above all, the
two groups did not significantly differ in reference to what extent
Neuronal Processing of Odors in Panic Disorder
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the four odors were correctly identified after each block [all
p..05].
Sweat sampling
Sweat was sampled under standardized conditions using an
odorless T-Shirt during two stress procedures: first, for the
sampling of ‘‘anxiety sweat’’, a psychosocial stress test of ten
minutes duration consisting of a self-presentation task and an
arithmetic task was realized (Trier Social Stress Test, TSST, [47]).
Second, for the sampling of the participants’ own control sweat, a
physical exercise condition (bicycle ergometry) of ten minutes
duration with resistance of ten Watt, a minimum of 110 bpm and
a maximum of 120 bpm was realized according to Pause et al. [48]
and Prehn-Kristensen et al. [20]. Sweat odor from a moderately
intense physical exercise condition was collected as sweat control
odor. This situation is typically perceived to be emotionally neutral
and associated with only increased physical but not anxious
arousal [20,48]. This point was proved by measuring the state
anxiety with the state version of the State-Trait-Anxiety-Inventory
(STAI) before and after the two stress conditions (TSST vs.
ergometry) [44]. Above all, the affective dimension of experienced
arousal was assessed using the Self-Assessment Manikin (SAM) as a
nine-point pictorial rating scale before and after both stress
conditions [49]. Both TSST and the ergometric exercise took
place on two separate days with a mean interval of 15.08 days
(SD=19.41 days, minimum: 2 days, maximum: 80 days). Both
tests lasted the same length of time and took place at the same time
of day [9]. The room temperature was assessed with a stationary
thermometer. The temperature was comparable between the
groups and the conditions (TSST, bicycle ergometry) with no
change throughout the test procedure. The patients were asked
not to use any deodorants, perfumed shampoos, and soaps the day
before and on the day of the sweat sampling. Moreover, the
participants were asked not to eat meals with odor-intensive
ingredients such as garlic, cabbage, or onions on both the day
before and on the day of the sweat sampling. In addition, on the
day of the sweat sampling the participants were asked to refrain
from alcohol, coffee, and smoking, and to wash their armpits with
an odorless soap shortly before the sweat sampling.
Both groups showed a significant increase in state anxiety over
time (main effect of time: F(1, 24) = 20.091, p,.001) with a
significantly higher increase during the TSST than during the
bicycle ergometry condition (interaction time x condition: F(1, 24)
= 13.032, p = .001). The two groups did not differ significantly
with respect to state anxiety between conditions (interaction group
x condition: F(1, 24) = .583, p,.452). According to the SAM,
both groups showed an increase in arousal (main effect of time:
F(1, 24) = 5.245, p = .031) with no significant difference between
conditions (interaction time x condition: F(1, 24) = .347, p= .561)
and groups (interaction group x condition: F(1, 24) = 1.215,
p = .281).
The sweat samples were stored air-tight to be deep-frozen at
280u Celsius in the central laboratory at the University Hospital
of the Dresden University of Technology, Dresden, Germany.
Stimulus Presentation
We used a two-factorial design with the between subject factor,
‘‘group’’ (PD vs. controls), and the within subject factor ‘‘odor’’.
Table 1. Characteristics of patients with Panic Disorder (PD) (N = 13) and healthy controls (N= 13). Displayed are the means and
standard deviations (S.D.) or percentages.
Patients with PD Controls (C) x2/U P
Total, N 13 13
Females, n (%) 6 (46.2) 6 (46.2)
Males, n (%) 7 (53.9) 7 (53.9) .000 1.000({)
Age (years) 31.10 (13.01) 24.82 (4.52) 70.000 .457(U)
Cycle week 2.00 (1.22) 2.00 (.89) 14.000 .848(U)
Oral contraceptives, n (%) 2 (33.33) 1 (16.67) .444 1.000({)
BMI (kg/m2) 22.26 (2.40) 23.64 (3.28) 64.000 .293
Smokers, n (%) 6 (46.2) 2 (15.4) 2.889 .202({)
Alcohol consumption, n (%) 8 (61.5%) 8 (61.5%) .000 1.000({)
Contraceptive pill, n (%) 2 (33.3) 1 (16.7) .749 .545({)
PAS 16.32 (12.91) 1.91 (4.66) 17.500 ,.001***(U)
STAI-Trait 41.92 (9.64) 33.77 (7.54) 45.500 .045*(U)
ACQ .95 (.52) .54 (.30) 45.000 .042*(U)
BSQ 1.50 (.78) 1.10 (.58) 61.000 .227(U)
MI alone .86 (.93) .24 (.40) 43.500 .035*(U)
MI accompanied .60 (.70) .08 (.11) 33.000 .008**(U)
BDI 10.69 (4.61) 3.85 (3.69) 18.000 ,.001***(U)
GSI (SCL), T-value 67.09 (9.55) 52.08 (10.42) 19.500 .003**(U)
STAI-TSST, pre/post 37.77 (9.68)/49.85 (12.59) 39.00 (10.19)/45.46 (6.16) 77.500/65.000 .719(U)/.316(U)
STAI-ergo, pre/post 37.50 (7.17)/39.15 (9.06) 34.54 (3.64)/34.46 (5.35) 68.000/72.000 .395(U)/.520(U)
***p,.001, **p,.01; *p,.05; { Chi-square test; U = Mann-Whitney U-Test; ACQ = Agoraphobic Cognitions Questionnaire [42]; BDI = Beck-Depression-Inventory [39];
BSQ = Body Sensations Questionnaire [42]; ergo = ergometry; GSI = General-Symptom-Index [40]; MI = Mobility Inventory [43]; PAS = Panic and Agoraphobia- Scale
[41]; SCL = Symptom Check List [40]; STAI = State-Trait-Anxiety-Inventory [44].
doi:10.1371/journal.pone.0074655.t001
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The odors presented were either the participants’ own sweat odor
(TSST sweat, ergometry sweat) or artificial odors (artificial sweat,
peach).
Each subject participated in four sessions with two different
body odors (TSST, bicycle ergometry) and two non-body odors.
As non-body odors, the artificial olfactory stimuli ‘‘peach’’ [Frey
und Lau GmbH, Henstedt-Ulzburg, Germany] and ‘‘artificial
sweat’’ [Unilever, Port Sunlight, UK] were used. Each one of the
four odors was presented birhinally in randomized order. The
peach odor and the artificial sweat odor were dissolved in
propylenglykol 1,2-propandiol (C3H8O2) 1:20. For the presenta-
tion of the sweat samples, the armpit area (10 by 10 cm) of the T-
Shirts worn during the different stress conditions (TSST, bicycle
ergometry) was cut out. The two swatches per sweat condition
were placed in a wash bottle blown through by a constant air flow.
Odors were presented intra-nasally (inner diameter of the
TeflonTM tubing: 4 mm; length: 5 m) [50]. To avoid mechanical
stimulation, the odor pulses were embedded in a constant flow of
odorless, humidified air of 2.5 l/minute [50]. Stimulus pulses had
a length of 2 seconds, the interval between the stimuli was 1
second. During the stimulus presentation, the participants were
trained to breathe synchronously. Before the stimulus presenta-
tion, the participants were not supplied with any information
about which stimulus would be presented. To ensure alertness,
each subject had to rate the perceived intensity (0 = extremely low
intensity; 10 = extremely high intensity) and the hedonic quality
(25= extremely unpleasant; +5 = extremely pleasant) of each
odor after each session.
FMRI Protocol and Data Analysis
We used a 1.5T scanner (Siemens Magnetom Avanto, Erlangen,
Sonata, Vision) for fMRI data acquisition. We utilized a blocked
factorial design and presented the odors via an olfactometer during
fMRI scanning to evoke the neural responses associated with the
olfactory stimuli as had previously been described by Croy et al.
[50].
For functional data, 96 volumes per session were acquired by
means of a 33 axial-slice matrix 2D SE/EP sequence (TR:
2500ms/TE:40ms, matrix = 64664, voxel size 36363mm, FoV
1152*1152). The sessions were randomized across the participants.
In each session, the participants received 8 scans during the 20s-
ON-block and 8 scans during the 20s-OFF-block according to
Croy et al. [50]. ON and OFF blocks were repeated six times, each
session lasting about 4 minutes. Additionally, T1-weighted images
were acquired by using a 3D IR/GR sequence (TR: 2180ms/TE:
3.93ms; FoV 256*280/352*384) to localize the activated areas.
The data analysis was performed with SPM 5 software (Statistical
Parametric Mapping; Wellcome Department of Imaging Neuro-
science, London, UK; www.fil.ion.ucl.ac.uk/spm), implemented in
Matlab 7.9.0 (R2009b, The Mathworks Inc., USA) following
spatial pre-processing with the same software (spatial filtering: high
pass filter 128Hz, realignment, normalisation using a standard EPI
template, smoothing by means of 86868 FWHM). There were no
significant group differences according to translational and
rotational movement parameters [translation in mm: T=2.545,
df = 24, p = .591, patients/controls:.58 (.42)/.49 (.36); rotation in u:
T= .941, df = 24,.941, patients/controls:.08 (.60)/.06 (.80)]. The
first three EPI images were discarded to allow the MRI signal to
reach a steady state. MNI-Coordinates of the activation are
presented. The localization of MNI-coordinates was realized with
the Anatomy-Toolbox [51] and was confirmed with WFU-
PickAtlas 2.4 [52] as well as the Talairach-Client [53]. The
analysis was based on one-sample and two-sample t-tests. Voxels
in MNI-space were considered statistically significant at a
threshold of p,.05 (corrected for multiple comparisons at cluster
level) using a height threshold of p,.001 uncorrected [50],
corresponding to T=3.26 and a cluster size of at least 10 activated
voxels according to a recommendation by Lieberman and
Cunningham [54]. In order to test our hypothesis of an altered
activation in the olfactory processing areas, we performed region
of interest (ROI) analyses with Small Volume Correction using
masks for primary (amygdalae, piriform cortex) and secondary
(orbitofrontal cortex, insula, hippocampus, thalamus) olfactory
areas according to Sobel et al. [33] and Zatorre and Jones-
Gotman [34]. The masks were created using the WFU PickAtlas
2.4 software [52]. Moreover, a hypothesis-driven ROI-analysis
was performed according to the coordinates reported by Pillay et
al. [25] for the anterior cingulate cortex [22 16 24] and
Wittmann et al. [30] for the inferior frontal gyrus [45 30 215]
using a sphere centered at these coordinates with a radius of
10 mm. The BOLD-signal was correlated with PAS scores using
Pearsons correlation analysis. For the correlation analysis, we
extracted the beta values (intensity) for the BOLD-contrasts which
were of interest (ergometry . TSST for patients . controls for the
cingulate gyrus [24 242 54] and TSST . ergometry for patients
. controls for the inferior frontal gyrus [42 36 210]). For each
subject, the beta value was imported in SPSS version 21.0.0.0.
Results
Odor Ratings
The odor ratings were analysed using the non-parametric
Mann-Whitney U Test and the Wilcoxon signed-rank test. P-value
was Bonferroni-corrected for multiple comparisons. There was no
group difference in the perceived intensity of the odors (Mann-
Whitney U Test-peach: U=56.500, p= .146; artificial sweat:
U= 60.000, p = .199; ergometry sweat: U= 76.500, p = .678;
TSST sweat: U= 55.000, p = .121). Independent of the group,
the peach odor was perceived as more intensive than the other
odors (Wilcoxon signed-rank test for patients compared with
artificial sweat: Z=22.908, p = .004; ergometry sweat:
Z=22.979, p = .003; TSST sweat: Z=23.219, p = .001; for
healthy controls compared with artificial sweat: Z=23.192,
p = .001; ergometry sweat: Z=22.914, p= .004; TSST sweat:
Z=23.195, p = .001). The other odors did not differ significantly
with respect to the perceived intensity in both groups (Wilcoxon
signed-rank test for patients- ergometry sweat vs. artificial sweat:
Z=2.051, p= .959; TSST sweat vs. artificial sweat: Z=2.447,
p = .655; TSST sweat vs. ergometry sweat: Z=21.799, p = .072;
for healthy controls- ergometry sweat vs. artificial sweat:
Z=22.176, p ..01; TSST sweat vs. artificial sweat:
Z=22.279, p ..01; TSST sweat vs. ergometry sweat:
Z=2.709, p = .478) (see Figure 1).
According to the judged valence of the odors, there was no
significant group difference between the healthy controls and the
patients with PD (Mann-Whitney U Test- peach: U=38.000, p
..01; artificial sweat: U= 83.000, p= .928; ergometry sweat:
U= 57.500, p = .161; TSST sweat: U= 54.000, p = .110). There
were no significant differences between the TSST sweat odor, the
ergometry sweat odor, and the artificial sweat odor in both groups
(Wilcoxon signed-rank test for patients- ergometry sweat vs.
artificial sweat: Z=21.535, p = .125; TSST sweat vs. artificial
sweat: Z=21.253, p= .210; TSST sweat vs. ergometry sweat:
Z=2.212, p= .832; for healthy controls- ergometry sweat vs.
artificial sweat: Z=2.278, p = .781; TSST sweat vs. artificial
sweat: Z=2.040, p = .968; TSST sweat vs. ergometry sweat:
Z=2.361, p = .718).
Neuronal Processing of Odors in Panic Disorder
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The sweat odors were rated as neutral to mildly unpleasant
while the peach odor was rated as significantly more pleasant than
the other odors (Wilcoxon signed-rank test for patients compared
with artificial sweat: Z=23.083, p = .002; ergometry sweat:
Z=22.943, p = .003; TSST sweat: Z=22.931, p = .003; for
healthy controls compared with artificial sweat: Z=22.901,
p = .004; ergometry sweat: Z=22.594, p = .009; TSST sweat:
Z=22.728, p= .006) (see Figure 1).
Main Effect of ‘‘artificial odors’’
First, we analyzed the main contrast ON- vs. OFF for artificial
odors (artificial sweat, peach) separately for both groups, focusing
on the aspect of olfactory processing. While the healthy controls
activated both primary and secondary olfactory areas, patients
with PD predominantly activated frontal areas not part of primary
or secondary olfactory processing areas (for details see Table 2).
Comparison between the groups for ‘‘artificial odors’’
We compared the odor - no odor contrasts for artificial odors
(peach, artificial sweat) of the patients with PD with the odor - no
odor contrasts of the healthy controls (odor . no odor; PD ./
,controls) and performed a Small Volume Correction for
coordinates of the anterior cingulate cortex [22 16 24] reported
by Pillay et al. in patients with PD [25].
The contrast revealed no suprathreshold activations of olfactory
processing areas in the group of patients with PD compared to the
healthy controls. However, the controls showed an increased
activation in the right thalamus, the right posterior cingulate
cortex, and the left anterior cingulate cortex compared to the
patients with PD (for details see Table 2 and Figure 2). The
comparison of both the odor - no odor contrasts during the
presentation of the artificial sweat odor and the peach odor did not
reveal any significant group differences.
Main Effect of ‘‘own body odors’’
Second, we analyzed the odor - no odor contrasts for own body
odors (anxiety sweat, ergometry sweat) separately for both groups.
While the patients with PD activated frontal and temporal areas
(see Table 3), the healthy controls activated parts of the limbic lobe
with the posterior and the anterior cingulate cortex (see Table 3).
In ROI-analyses, both groups did not show a significantly
enhanced activation in areas that are typically involved in the
processing of olfactory stimuli such as the primary olfactory cortex
(e.g. piriform cortex, amygdalae, entorhinal cortex) or the
secondary olfactory cortex (e.g. thalamus, hypothalamus, hippo-
campus, insula, orbitofrontal cortex). Only the patients with PD
showed enhanced activation of the orbitofrontal cortex as part of
the secondary olfactory area.
Comparison between the groups for ‘‘own body odors’’
The comparison of the odor - no odor contrasts during the
presentation of ergometry sweat revealed more brain activation in
the superior temporal gyrus and the supramarginal gyrus in the
patients with PD than in the healthy controls (see Table 3). There
were no significant group differences when the odor-no odor
contrasts during the presentation of anxiety sweat were compared.
When the two sweat conditions were compared between groups,
the patients showed more brain activation under the presentation
of the ergometry sweat odor compared to the anxiety sweat odor
in the cingulate cortex and the supramarginal gyrus. The
activation in the left cingulate cortex was positively correlated
with the total score in the Panic- and Agoraphobia-Scale (PAS)
(Pearsons r = .465, p = .017, see Figure 3a). Moreover, correla-
tions were found with the subscales of the PAS: agoraphobic
avoidance (Pearsoǹs r = .540, p= .004), anticipatory anxiety
(Pearsons r = .488, p = .011) and health concerns (Pearsons r
= .406, p = .040).
The comparison of the odor - no odor contrast during the
presentation of the anxiety sweat odor did not reveal any
significant group differences. In a ROI-analysis according to the
MNI-coordinates [42 36 210] reported by Wittmann et al. [30],
patients with PD showed more brain activity in the inferior frontal
gyrus under the presentation of anxiety sweat odor compared to
ergometry sweat odor. This was positively correlated with the total
Figure 1. Intensity and hedonic ratings. Displayed are mean values and one-sided standard deviations for artificial odors (peach, artificial sweat)
and own body odors (TSST sweat, ergometry sweat) in patients with PD and healthy controls. Intensity Ratings: 0 (no odor) 2 10 (very strong
intensity); Hedonic rating: 25 (very unpleasant) 2 +5 (very pleasant). ***p #.001, **p #.01
doi:10.1371/journal.pone.0074655.g001
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score in the Panic- and Agoraphobia-Scale (PAS) (Pearsons r
= .462, p = .017, see Figure 3b). Moreover, correlations were
found with the subscales of the PAS: agoraphobic avoidance
(Pearsoǹs r = .493, p = .010), anticipatory anxiety (Pearsons r
= .442, p = .024) and health concerns (Pearsons r = .468,
p = .016).
Discussion
Recent findings showed an overlap between a panic-specific fear
network, neuronal areas associated with emotional processing, and
the olfactory projection areas [4,5,23,24,32]. Therefore, the
present study focused on the neuronal processing of odors gained
Table 2.Relative increases in brain activity under the presentation of artificial odors.
Region x y z T(Z)-Score kE (voxels)
artificial odors . no odor, patients with PD
Frontal Lobe Inferior Frontal Gyrus 250 30 16 5.85 (4.60) 706
Middle Frontal Gyrus 250 22 34 5.66 (4.50) #
Precentral Gyrus 242 6 46 4.30 (3.68) #
Superior Medial Gyrus 22 28 42 5.66 (4.50) 94
Supplementary Motor area (SMA) 210 20 46 3.74 (3.30) #
Primary olfactory areas1 — no supratreshold voxels —
Secondary olfactory areas1 — no supratreshold voxels —
artifical odors . no odor, healthy controls
Corpus Callosum 0 6 16 7.01 (5.16) 1199
26 26 22 6.82 (5.08) #
6 24 20 6.30 (4.83) #
Sublobular Nucleus Caudatus 18 16 18 5.42 (4.37) #
Limbic Lobe Cingulate Gyrus 26 26 22 6.82 (5.08) #
Parahippocampal Gyrus 10 236 0 4.40 (3.75) #
Mammillary Body 4 26 212 3.98 (3.47) 100
Frontal Lobe Inferior Frontal Gyrus 244 42 12 6.38 (4.87) 201
Middle Frontal Gyrus 242 46 24 4.03 (3.50) #
Temporal Lobe Inferior Temporal Gyrus 60 242 210 4.55 (3.85) 106
Middle Temporal Gyrus 64 242 214 4.41 (3.76) #
Parietal Lobe Precuneus 224 252 10 4.84 (4.03) 89
Calcarine Gyrus 226 260 10 4.49 (3.81) #
Primary olfactory areas Amygdala
1
18 26 220 4.59 (3.87) 28
18 28 216 4.44 (3.77) #
Secondary olfactory areas Insula
1
242 216 10 4.59 (3.88) 37
246 210 4 3.89 (3.41) #
Orbitofrontal Cortex
1
46 54 0 5.18 (4.23) 35
46 38 214 5.03 (4.14) 30
artificial odors . no odor, patients with PD . healthy controls
— no supratreshold voxels —
artificial odors . no odor, healthy controls . patients with PD
Thalamus 8 234 2 4.19 (3.86) 121
8 228 4 4.17 (3.85) #
Limbic Lobe Posterior Cingulate 10 238 8 3.96 (3.67) #
Anterior Cingulate
2
0 22 28 3.95 (3.67) 35
Primary olfactory areas1 — no supratreshold voxels —
Secondary olfactory areas1 Thalamus 8 228 4 4.17 (3.85) 25
6 226 8 4.03 (3.73) #
Brain activation for the contrast artificial odors . no odor for the pooled odors peach and artificial sweat for patients with PD (N= 13), controls (N = 13) and for patients
. controls/controls . patients. Whole brain analyses are corrected at cluster level and uncorrected at a height threshold of p,.001.
All activations are significant at p,.05, corrected for multiple comparisons at the cluster level (with a height threshold of p,.001, uncorrected). 1 = p,.05 in a
hypothesis-driven region-of-interest (ROI) analysis. Brain masks were created using WFU PickAtlas. 2 = p,.05 in a hypothesis-driven region-of-interest (ROI) analysis
according to the coordinates reported by by Pillay et al. [25] for the anterior cingulate cortex [22 16 24].
# indicates that this activation maximum is part of the same cluster.
For each region of activation, the coordinates of the maximally activated voxels within the activation cluster are given in standard stereotactic MNI space.
doi:10.1371/journal.pone.0074655.t002
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under potential psychosocial threat and under physical exercise in
patients with PD. It was hypothesized that the presentation of
odors gained during potentially threatening situations might
trigger a panic-specific fear-network in patients with PD [4].
Under the presentation of own body odors (TSST sweat,
ergometry sweat), patients with PD showed activations in inferior
frontal, superior temporal, and orbitofrontal areas while healthy
controls also activated cerebellum and limbic lobe structures such
as the cingulate and the posterior cingulate cortex.
When the two sweat conditions were compared between the
groups, the patients showed more brain activity under the
presentation of the ergometry sweat odor compared to the TSST
sweat odor in the cingulate gyrus and supramarginal gyrus. An
increased activation in the cingulate cortex was accompanied by
an increased total score of the Panic- and Agoraphobia-Scale,
increased agoraphobic avoidance, anticipatory anxiety, and health
concerns. Under the presentation of the TSST sweat odor
compared to the ergometry sweat odor, the patients with PD
showed more brain activity in the inferior frontal gyrus. The latter
was also positively correlated with the total score in the Panic- and
Agoraphobia-Scale, agoraphobic avoidance, anticipatory anxiety,
and health concerns.
The patients with PD predominantly activated inferior
frontal parts rather than the amygdalae under the presentation
of their own body odors. This is in line with the literature
showing lacking activation of the amygdalae even under the
presentation of panic-specific stimuli e.g. panic-related words,
fearful faces, or panicogenic agents [fMRI studies: e.g.
23,24,25,26,55]. This lacking activation of limbic areas has also
been shown in patients with schizophrenia who rather showed an
extensive ventral, medial, and dorsolateral frontal activation while
failing to activate limbic and paralimbic regions under the
presentation of an unpleasant odor stimulus [56]. Crespo-Facorro
and colleagues concluded that the enhanced activation of
prefrontal brain regions might be compensatory for the failure of
the limbic/paralimbic regions to distinguish unpleasant from
pleasant or neutral stimuli [56]. This activation pattern might also
occur in patients with PD and might be accompanied by the
panic-specific overestimation of threat and negative consequences
as well as a pre-attentive processing of negative stimuli [1,5,56]. In
addition, a lacking activation of the amygdalae under the
presentation of stress-related sweat odors in patients with PD
might also be due to the fact that in the present study moderately
unpleasant olfactory stimuli and no specific panic-related odors
such as odors gained during first-time sky diving were used [9,30].
With respect to their own body odors, the patients with PD
showed an enhanced activity predominantly in the inferior frontal
gyrus. Based on the neuroanatomical model, activation in the
medial prefrontal cortex is associated with anticipatory anxiety
and avoidant behaviour [4]. The medial prefrontal cortex plays an
important role for the information processing of ones own and
others emotional states [57], the formation of dysfunctional
interpretation of somatic symptoms, and agoraphobic avoidance
[4]. Previous findings could show a correlation between the
activation of the inferior prefrontal cortex with the severity of
psychopathology [58,59,60], anticipatory anxiety [23,30,61], and
avoidant behaviour in patients with PD [62]. Recent results from a
differential conditioning paradigm were able to show an increased
activation of the inferior frontal gyrus during exteroceptive fear
conditioning [31]. The authors conclude that an increased activity
of the inferior frontal gyrus is related to enhanced top-down
control when risk assessment and threat evaluation take place. In
the present study, an enhanced activity of the inferior and
orbitofrontal cortex could be shown for the presentation of own
Figure 2. Activated clusters for the contrast artificial odors (peach, artificial sweat) . no odor. The contrast is displayed for the healthy
controls compared to patients with PD (K$10, p,.05). For visualization a normalized template provided by SPM5-Software (single_subj_T1.nii) was
used. *p,.05 in a hypothesis-driven region-of-interest (ROI) analysis according to the coordinates reported by Pillay et al. [25] for the anterior
cingulate cortex [22 16 24].
doi:10.1371/journal.pone.0074655.g002
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body odors. Also, own body odors from stressful situations might
display potentially threatening stimuli, increasing the necessity to
enhance top-down control and behavioural inhibition in order to
show an adaptive behavioural response [31,63].
In addition, the presentation of artificial odors led to a
reduced activation of the anterior cingulate cortex and
the posterior cingulate cortex in the patients with PD. Recent
findings from a previous study showed a reduced activation of the
anterior cingulate cortex under the presentation of neutral (coffee)
to very pleasant (peach) odors in patients with childhood
maltreatment [50]. In patients with PD, a reduced activation of
both the amgydalae and the anterior cingulate cortex could be
observed under the presentation of fearful stimuli (faces) [25].
Even under remitted psychopathology, a reduced activation of the
anterior cingulate cortex could be found for not-panic-specific
word-face pairs in patients with PD [27]. The anterior and
posterior cingulate cortex play an important role for selective
attention [64], emotional evaluation, and modulation [64,65].
Patients with PD show selective attention towards threat [66] and
enhanced recruitment of episodic memory structures located in the
posterior cingulate cortex [24,67], which is activated in a sustained
way during baseline-conditions and thus deactivated under
stimulation [68]. Furthermore, patients with PD reduce their
attentional resources when faced with a threatening situation as an
adaption strategy based on their chronic hyper-arousal in order to
prevent a possible somatic/neuronal over-reaction. This might be
reflected in a reduced activity of the anterior and posterior
cingulate cortex [25].
Thus, one might conclude that the artificial odors led to an
enhanced arousal accompanied by a modulation of attentional
resources away from a subsequent potential threat to maintain
their ability to react and not to be overwhelmed [25].
In the present study, we found reduced activity of the
thalamus under the presentation of artificial odors. The
thalamus is a major part of the fear-network [4] which regulates
the attentional processes, memory, and speech by involving the
efferents from the amygdalae to the thalamus [69]. The thalamus
has a pivotal role in the coordination of neocortical attentional
control systems and the maintenance of attention. A disturbed
neuronal transmission of sensory information from the thalamus to
the amygdalae, the anterior cingulate cortex, and the hippocam-
pus might therefore increase the susceptibility to experiencing
anxiety symptoms [70]. These processes might be altered under
the presentation of olfactory stimuli in patients with PD.
The strengths of the present study are the use of a structured
clinical diagnostic interview (SCID, [36,37]) for the assessment of
PD and the inclusion of patients without other psychiatric
comorbidities as well as psychotropic drug treatment or medica-
Table 3. Relative increases in brain activity under the presentation of own body odors.
Region x y z T(Z)-Score kE (voxels)
own body odors . no odor, patients with PD
Frontal Lobe Inferior Frontal Gyrus 248 14 0 5.38 (4.35) 63
Temporal Lobe Superior Temporal Gyrus 48 210 0 4.03 (3.51) 57
Primary olfactory areas1 — no supratreshold voxels —
Secondary olfactory areas1 Orbitofrontal Cortex* 248 16 0 4.69 (3.93) 12
own body odors . no odor, healthy controls
Temporal Lobe Superior Temporal
Gyrus
32 246 10 5.05 (4.16) 93
Limbic Lobe Cingulate Gyrus 218 238 16 4.08 (3.54) 56
Posterior Cingulate 210 230 22 4.41 (3.76) 47
Cingulate Gyrus 212 222 24 4.09 (3.54) #
Primary olfactory areas1 — no supratreshold voxels —
Secondary olfactory areas1 — no supratreshold voxels —
ergometry . no odor, patients with PD . healthy controls
Temporal Lobe Superior Temporal Gyrus 52 232 16 4.31 (3.67) 40
Parietal Lobe Supramarginal Gyrus 52 230 24 4.17 (3.58) #
TSST . no odor, patients with PD . healthy controls
— no supratreshold voxels —
ergometry . TSST, patients with PD . healthy controls
Limbic Lobe Cingulate Cortex 24 242 54 4.51 (3.80) 41
Parietal Lobe Supramarginal Gyrus 48 226 34 4.58 (3.84) 40
TSST . ergometry, patients with PD . healthy controls
Frontal Lobe Inferior Frontal Gyrus
2
42 36 210 5.14 (4.18) 21
Brain activation for the contrast own body odors . no odor for the pooled odors TSST sweat and ergometry sweat for patients with PD (N= 13), controls (N = 13) and for
patients . controls/controls . patients. Whole brain analyses are corrected at cluster level and uncorrected at a height threshold of p,.001.
All activations are significant at p,.05, corrected for multiple comparisons at the cluster level (with a height threshold of p,.001, uncorrected).
1 = p,.05 in a hypothesis-driven region-of-interest (ROI) analysis. Brain masks were created using WFU PickAtlas. 2 = p,.05 in a hypothesis-driven region-of-interest
(ROI) analysis according to the coordinates reported by Wittmann et al. [30] for the inferior frontal gyrus [45 30 215].
# indicates that this activation maximum is part of the same cluster.
For each region of activation, the coordinates of the maximally activated voxels within the activation cluster are given in standard stereotactic MNI space.
doi:10.1371/journal.pone.0074655.t003
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tion with impact on the olfactory system. Healthy controls were
matched by age and gender. A block design was used which allows
a large BOLD- signal change [71].
Our results should be interpreted within the context of
methodological limitations. In the present study, approximately
two thirds of the patients with PD had a remitted to mild severity
of PD. The mild symptom severity might be responsible for the
findings that specific neuronal areas such as the amgydalae (which
is usually activated to trigger flight or fight behaviour in PD), do no
longer show any enhanced activation [72]. Therefore, future
studies should include a group of patients with more severe
psychopathology. Moreover, future studies should also include a
patient control group in order to investigate whether the neuronal
alterations in olfactory processing are specific to patients with PD.
In order to exclude alterations in the breathing regime, future
studies should control breathing by way of a chest belt and supply
support via computerized visual cues clearly indicating inhalation
and exhalation phases [9,20].
Brain activity data were analyzed using a rather flexible height
threshold of p,.001 (uncorrected) with a correction for multiple
comparisons at cluster level. Although this approach is in line with
a former study that used a similar kind of low-potent odor stimuli
[50], future studies could apply more conservative thresholding in
a larger sample. As another limitation, patients with PD did not
show activations of primary and secondary olfactory processing
areas. In general, due to the small sample size, the group
differences may not have been detected and, hence, the data
should be interpreted with caution. The findings should be
replicated in a larger sample of patients with PD. In order to elicit
the amygdalae activation, future studies might apply more panic-
specific and more potent body odor stimuli such as sweat odor
generated during a first-time tandem skydive [9].
In summary, our findings suggest some differences in the
neuronal processing of stress-related body-odors and artificial
odors in patients with PD. These differences in the neural activity
might be associated with an increased severity of the psychopa-
thology and dysfunctional threat-related cognitive processing. The
differences in olfactory processing might display a vulnerability
factor in patients with PD, which might even be sustained in
patients with a mild or remitted psychopathology.
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Figure 3. Activated cluster for the contrast ergometry sweat odor . TSST sweat odor (Fig. 3a). The contrast is displayed for the
comparison of patients with PD and healthy controls (K$10, p,.05). Patients showed more activation in the left cingulate cortex than healthy
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frontal gyrus than healthy controls. The activated clusters were significantly positive correlated with the severity of psychopathology on the PAS [41].
For visualization, we used a normalized template, provided by SPM 5- Software (single_subj_T1.nii).
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